Thanks, Nick, and good morning to everyone. As Nick mentioned, this quarter represents the 14th consecutive quarter of free cash flow generation through the execution of our sustainable business model and long-term strategic plan. During the quarter, we generated approximately $135 million of free cash flow, including the proceeds from the previously announced non-op sale. Since we initially laid out our free cash flow plan in the first quarter of 2020, this brings our cumulative free cash flow to approximately $1.8 billion, which is roughly 60% of our current market cap. We are well on our way and continuing to execute our long-term free cash flow generation plan, and we believe that we remain well positioned to take advantage of any deepening valuation disconnects that might occur in either the data equity markets. We also continue to believe that our shares trade at a significant discount to their intrinsic value, and we will continue to take advantage of this opportunity moving forward to drive our share count lower and free cash flow per share higher. More on that shortly. On the balance sheet side, we have constructed our debt maturities and leverage profile to reduce risk and enable maximum flexibility when making capital allocation decisions. Our overall objective of maintaining a low-risk balance sheet through active debt maturity management, and lowering overall absolute debt is unchanged. Our significant maturity runway and robust hedge book provides visibility into the future that underpins our capital allocation flexibility. Moreover, as we have consistently demonstrated, our capital allocation plan is intended to be fluid and will adjust as the underlying variables adjust, the most important variable currently being our equity valuation, while we have been consistent in signaling our desire to achieve lower absolute debt levels, the timing of that delevering is an output of running the clinical capital allocation math. As we've seen over the last few quarters, we expect leverage ratios to tick up and down as underlying EBITDA adjusted commodity prices. Further, absolute debt levels may also fluctuate in the short term based on the timing of free cash flow deployment. However, any such fluctuations are merely short-term noise. Before turning to the updated guidance for 2023, I want to touch on 3 key themes that we see unfolding moving into 2024 and beyond that drive our confidence in our ability to materially grow long-term free cash flow per share. First, we expect nat gas realizations to increase in 2024 and beyond as forward NYMEX strip prices are increasing over the same period. The macro backdrop of strong long-term fundamentals for natural gas demand due to natural gas serving as the cornerstone of our world's energy mix will provide a material boost to our cash flows as we move beyond the near-term pricing environment. Second, as we've previously guided to, we expect higher levels of production in 2024 and capital levels to decline materially moving forward in 2024 and beyond. As a result of the current operational successes we're experiencing, beginning in 2024 and beyond, we are expecting to grow volumes over 2023 levels to approximately 580 Bcfe. Holding production at that level beyond 2024 then provides us clear line of sight to driving capital intensity materially lower in 2024 and below $500 million annually by 2025. This assumes no change in current service cost pricing, but is driven instead by the lower capital intensity needed to maintain our projected 2024 production levels moving forward. This would return us to maintenance capital levels similar to those initially contemplated as part of our 7-year plan with the exception of the higher current service costs and about 20 Bcfe a year more of production compared to that original plan. The third key theme is that our new technologies group is now cash flow positive. As we discussed on prior calls, there are 3 main categories that the New Tech Group has been pursuing. One, expanding alternate fuel markets such as CNG, LNG and hydrogen; two, developing oilfield services technologies that lower cost and reduce emissions; and three, attaining value recognition for the environmental attributes tied to our waste methane abatement operations. The latter of these 3 being the most progressed in terms of impacting free cash flow in the near term. For the quarter, we recorded approximately $8 million in revenue associated with environmental attributes. We are still in the very early stages of developing these opportunities, but to provide some color on the near-term magnitude of their impact, we believe we have line of sight on the new technologies group contributing approximately $75 million in free cash flow annually starting in 2024 with the potential of achieving up to $100 million. Additionally, we expect this annual free cash flow from the New Tech Group to grow meaningfully higher in the years beyond 2024. The potential is truly exciting, and we look forward to providing more updates in detail on these projections in the coming quarters. When you consider these 3 factors together, it is easy to see the free cash flow per share potential of the company in the coming years. They also make for a very easy capital allocation decision to continue reducing our share count. The overall trend is clear. Unless our share price materially re-rates, we expect our outstanding shares will continue to shrink dramatically over the next several years, contributing to further growth in our free cash flow per share. Now let's shift to our updated 2023 outlook on Slide 6 to clarify how we see the remainder of the year unfolding. We have updated each of the major guidance components for the impact of the non-op sale that occurred during the quarter and have adjusted our EBITDA and free cash flow outlook for the year to reflect that transaction as well and to reflect the decline in near-term commodity prices that occurred during the quarter. Starting with production. The key takeaway, as Nick and Nav mentioned, is that our operational progress for 2023 has been excellent on a wellhead basis, we remain on track with the initial plan for 2023 after adjusting for the non-op sale. The adjustments we are making to narrow our production range to between 545 and 555 Bcfe are being driven by 3 factors. First, we've removed approximately 9 Bcfe of volumes associated with the non-op sale. As a reminder, the effective date of that sale was April 1, and the asset was producing approximately 33 million cubic feet equivalent per day. The second adjustment is related to lower expected ethane recoveries for the year. One of our key downstream counterparties has been unable to take the ethane volumes initially forecasted due to their plant start-up challenges. And as such, that ethane has remained in the gas stream have been sold for heat value. The bottom line is that due to penalty provisions in our contract with this customer, our overall free cash flow for the year has not been impacted by this. However, we expect our reported production equivalent volumes for 2023 to be approximately 9 Bcfe lower than they would have been had the ethane been recovered as planned. Lastly, due to the operational efficiencies, we expect to offset approximately 3 Bcfe of the non-op and ethane adjustments. In summary, despite the noise associated with the 2 downward adjustments, the key takeaway is that the operations are successfully on track with our plan. And as such, and as stated earlier, we are also reaffirming our production outlook for 2024, which is now approximately 580 Bcfe after updating our prior guidance of approximately 590 Bcfe to reflect an estimated 10 Bcfe impact of the non-op sale on next year's volumes. Next, turning to capital. The second quarter included spend associated with running 2 rigs and 1 completion crew for the entirety of the quarter. The second horizontal drilling rig has been recently released, which will result in the cadence of capital spend moving sequentially lower through the remainder of the year. On the service cost side, while we have seen some modest downward movements in certain categories, there has not been enough downward movement to materially impact projected 2023 capital levels. As such, we are moving the lower end of our capital range is up to reflect this. Moving forward, we are optimistic we may see further reductions on the service cost side as we head into 2024, and we will provide color on that in future calls as that outlook becomes clearer. One last point on capital. As we touched on earlier, our 2023 activity set and corresponding capital expenditures represent more than a maintenance of production plan. This level of capital spend allows us to keep an efficient operational pace that results in production volume growth from 2023 to 2024. Additionally, despite no changes to the current plan at this time, should forward gas prices decline further throughout the year, we will not hesitate to adjust our capital activity set in accordance with our focus on achieving the best long-term economic results. Lastly, on guidance, we've also increased our free cash flow outlook for 2023 to approximately $325 million. This update includes the onetime proceeds from the non-op sale, offset by roughly $12 million free cash flow decrease due to the same non-op sale and a roughly $35 million decrease due to the continued decline in commodity prices experienced during the quarter. However, despite the near-term commodity headwinds on a per share basis due to the continued reduction in shares that occurred during the quarter and the increased overall total free cash flow, we are now projecting 2023 free cash flow per share to increase by 33% to approximately $2 per share before any future share count reductions that may occur during the remainder of the year. To conclude, we are confident that the sustainable business model that we have created will continue to deliver value to our shareholders throughout the entire cycle. Our focus for the remainder of 2023 will remain on safe and compliant execution to develop our extensive natural gas asset base, accelerating free cash flow growth from our new technologies business on consistent and clinical capital allocation to grow our long-term free cash flow per share and most importantly, as always, on ensuring all of our decisions continue to reflect a long-term owner mindset. With that, I will turn it back over to Tyler for Q&A.